Vera's Trutakna meets Phase 3 endpoints in IgAN, cuts death risk

Vera Therapeutics reported positive final Phase 3 data for Trutakna in IgA nephropathy, showing stabilized kidney function and reduced risk of death and complications. The results are company-reported and not yet peer-reviewed; regulatory filing and market impact are pending. This strengthens Vera's competitive position in a niche renal space.